论文部分内容阅读
目的对GnRHa治疗特发性中枢性性早熟(ICPP)效果进行评价,并对影响其疗效的相关因素进行探讨。方法对72例特发性中枢性性早熟患儿治疗中进行定期随访,对患儿实际年龄、骨龄和身高的变化进行观察比较。根据患儿身高和骨龄的变化对成年期终身高进行预测,观察药物对患儿治疗后预测身高(PAH)的影响,并对影响GnRHa药物治疗疗效的相关因素进行分析。结果GnRHa治疗2年后SDSca由1.10±1.12下降到0.80±1.07,SDSba由-1.98±1.01升高到-0.97±1.48,PAH由(152.93±8.10)cm增加到(158.93±9.01)cm。对照组的患儿虽保持了比较高的生长速度,但是其SDSca、SDSba无显著变化,PAH由(157.81±9.53)cm下降到(150.69±12.43)cm。经统计学处理,GnRHa治疗后PAH与治疗开始时CA和BA的差值和BA/CA值呈负相关,与治疗开始的SDSba呈正相关,并与SDS呈负相关。结论GnRHa治疗后患儿PAH增加,其PAH与治疗前身高、SDSca、SDSba、BA和CA的差值有相关关系。
Objective To evaluate the effect of GnRHa on the treatment of idiopathic central precocious puberty (ICPP) and to explore the related factors that affect its curative effect. Methods 72 patients with idiopathic central precocious puberty were followed up regularly. The changes of actual age, bone age and height of the children were observed and compared. According to the changes of height and skeletal age of children, the height of adults was predicted, and the effect of drugs on the predicted height (PAH) after treatment was observed. The related factors that influenced the therapeutic effect of GnRHa were analyzed. Results SDSca decreased from 1.10 ± 1.12 to 0.80 ± 1.07 after two years of GnRHa treatment, while the SDSba increased from -1.98 ± 1.01 to -0.97 ± 1.48. The PAH increased from (152.93 ± 8.10) cm to (158.93 ± 9.01) cm. Although the control group had a relatively high growth rate, there was no significant change in SDSca and SDSba, and the PAH decreased from (157.81 ± 9.53) cm to (150.69 ± 12.43) cm. Statistically, there was a negative correlation between PAH and BA / CA and BA / CA at the beginning of treatment after GnRHa treatment, positively correlated with SDSba at the beginning of treatment, and negatively correlated with SDS. Conclusion The PAH in children with GnRHa increased after treatment, and the correlation between PAH and height, SDSca, SDSba, BA and CA before treatment.